Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Oct 8, 2024 (2 years ago)

Liceout

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP violations.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

LICEOUT, Liquid Lice Treatment for Human Use, Contents: 128 FL OZ. (3785.4 mL mL) per jug, Distributed By: Bob Barker Company, Inc., 7925 Purfoy Road, Fuquay-Varina, NC 27526. NDC: 53247-124-02

Affected NDC 53247-0124-02

Compare with the code on your package — it is the most precise check available.

Recalling firm
Neogen Corporation
Origin
KY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0074-2025 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other recalls by Neogen Corporation

All 2024 recalls
Class II · Moderate risk

Liceout

CGMP violations.

Ongoing cGMP deviation Neogen Corporation D-0073-2025

Other cgmp deviation recalls from 2024

All cgmp deviation recalls
Class II · Moderate risk

Henry Schein

CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.

Terminated cGMP deviation Keystone Industries D-0148-2025